Brief: Innovent Biologics Says Nmpa Approves Second New Drug Application Of Ros1 Inhibitor Dovbleron
03/01/2025 24:21
Jan 3 (Reuters) - Innovent Biologics 1801.HK :
* NMPA APPROVES SECOND NEW DRUG APPLICATION OF ROS1
INHIBITOR
DOVBLERON
Further company coverage: 1801.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis